Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 trial

print
PRINT
insite
SEARCH

Roy Fleischmann gives his perspective on the FINCH 1 trial results (1:58)

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT

Related content

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 and FINCH 3 trials

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The FINCH 1 trial

13-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Support for filgotinib use in RA patients with inadequate response to methotrexate
Image Credits